# Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

> **NCT03656094** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 98 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Pembrolizumab plus chemotherapy
- **DRUG:** Placebo plus chemotherapy

## Key facts

- **NCT ID:** NCT03656094
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2020-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656094, "Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03656094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*